Data as of Q4 2025 (Dec 31, 2025)

Burning Rock Biotech Limited

(BNR)

Financial Statements · SEC EDGAR XBRL

Revenue
$77.2M
+9.2%
Net Income
-$7.9M
+83.3%
Gross Margin
74.7%
Op. Income
-$7.8M
+84.0%
FCF
-$4.8M
+64.0%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Research & Development
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Pre-Tax Income
Income Tax Expense
Net Income
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$77.2M
$70.7M
$75.7M
$81.7M
$79.7M
$77.2M
$70.7M
$75.7M
$81.7M
$79.7M
$19.5M
$21.0M
$24.5M
$26.6M
$22.6M
$57.6M
$49.6M
$51.2M
$55.1M
$57.1M
$23.8M
$31.8M
$48.9M
$61.2M
$57.7M
-$7.8M
-$49.0M
-$94.3M
-$142.1M
-$125.1M
-
-
-
-
$241K
-$7.7M
-$46.7M
-$91.7M
-$140.5M
-$124.9M
$223K
$806K
$336K
$288K
$141K
-$7.9M
-$47.5M
-$92.1M
-$140.8M
-$125.0M
-
-
-
-
0